Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy

被引：34

作者：

Triantos, C ^{[1
]}

Samonakis, D ^{[1
]}

Stigliano, R ^{[1
]}

Thalheimer, U ^{[1
]}

Patch, D ^{[1
]}

Burroughs, A ^{[1
]}

机构：

[1] Royal Free Hosp, London NW3 2QG, England

来源：

TRANSPLANTATION | 2005年 / 79卷 / 03期

关键词：

liver transplantation; hepatitis C; interferon; ribavirin;

D O I：

10.1097/01.TP.0000149696.76204.38

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiviral therapy for recurrent hepatitis C after liver transplantation is increasingly used. This systematic review presents both viral and histological response in three areas: pretransplant (5 studies/180 patients), preemptive therapy soon after transplant (10 studies/417 patients), and therapy for established disease (75 studies/2027 patients). There were only 16 randomized studies (543 patients). Significant dose reductions and drug stoppage rates occurred. The data on histological improvement and risk of rejection are conflicting. Even the best antiviral therapy (pegylated interferon/ribavirin) is neither easily used nor reasonably effective. The best strategy will be pretransplant treatment, most likely with newer agents.

引用

页码：261 / 268

页数：8

共 78 条

[71] Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation [J].